Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check45 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check52 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check73 days agoChange DetectedThe website has updated the type of intervention to 'Verified 2016-12 by Angimmune LLC' and noted that the last known status is 'Not yet recruiting', while also revising the version from v2.13.3 to v2.14.0.SummaryDifference0.7%
- Check102 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.